Lactose supplier DFE Pharma has announced the availability of analytical services for dry powder inhaler formulations at its Closer to the Formulator (C2F) Center of Excellence in Hyderabad, India, in response to growing demand. According to DFE, the center opened in 2022 but only offered services for oral solid dosage forms until now.
Newly available services at the Hyderabad Center of Excellence include analytical method development, RLD characterization, and stability studies. The company notes that new resources also include anatomical throats and “respiratory dissolution profiles endorsed by the FDA” and that inhalation experts located at the site can perform realistic in-vitro lung deposition studies for in-vitro in-vivo correlation (IVIVC).
Director of the C2F Center of Excellence Anilkumar Gandhi commented, “We are thrilled to announce this expansion of our C2F Center of Excellence. With this investment in DPI expertise, we will support global customers working on inhaled products development, to bring drugs to market quickly and cost-effectively.”
Read the DFE Pharma press release
